Antibiotics – The Next Big Thing, Again?

Moderator: 

  • Danielle Marra, Associate Principal, Defined Health

Panelists: 

  • Dov Goldstein, MD, MBA, Aisling Capital LLC
  • Daniel S. Shapiro, MD, Professor of Internal Medicine, University of Nevada School of Medicine,  Department of Internal Medicine
  • Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital LLC

Early in this century, the global threat caused by antimicrobial resistance began to grab headlines.  Today, despite years of intensified warnings about resistant bacteria and the infections they cause, the situation remains largely unchanged and in some cases progressively worse.  A multitude of pathogens, including CRE, C. difficile, and Neisseria gonorrhoeae continue to exhibit resistance to available drug classes, with some strains showing pan-resistance, even to last resort products such as colistin. 

These last few years have also seen a noticeable lack of investment in antibiotics. An imposing mix of scientific and commercial challenges have resulted in several large pharma companies quietly exiting the space, and those who have remained have seen only modest progress.  More recently, however, several national and international policy and research initiatives (e.g., GAIN Act, BARDA, 10 x ’20, New Drugs 4 Bad Bugs) are reinvigorating the field and opening the door for new entrants, particularly biotechs.  These programs, coupled with some renewed activity from pharma (via the likes of Merck, GSK, and most recently, Pfizer) have spurred interest among the investment community, as both venture capital funding and deals in the antibiotic space have increased markedly. 

This webinar aims to uncover the drivers behind the heightened interest in anti-infectives.  Most importantly, will the expansion and recognition of unmet need together with initiatives to spur development be sufficient to overcome the significant concerns about commercial risk?  Please join us as we discuss the mechanisms by which both commercial and scientific risks are being reduced in antibiotic R&D, what drug developers in this space can do to justify continued interest and investment, and key considerations for investing in antibiotic companies.